EUTM file information
018418223
KYMERA
March 4, 2021
Trademark Summary
The trademark KYMERA was filed by Kymera Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on March 11, 2021, and received one opposition filed on June 10, 2021 by Idorsia Pharmaceuticals Ltd on Likelihood of confusion. the opponent was represented by Schade, Mirko Kai and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued June 10, 2021
The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on November 8, 2021.
Goods And Services
- The mark was filed in class 5 with following description of goods:
- Pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases
- Pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases
- Diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases.
- The mark was filed in class 42 with following description of goods:
- Research and development of therapeutic drugs for the treatment of oncology, autoimmune, immune-oncology and other related diseases
- Research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals
- Development of pharmaceutical preparations and medicines
- Drug development and discovery
- Medical research for development of therapeutic modalities for treatment of diseases
- Assays and reagents for use in scientific and biomedical research
- Clinical studies
- Preclinical and clinical development of therapeutic products.
